UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

 

FORM 8-K
CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

_______________________

Date of Report: August 10, 2017 (Date of earliest event reported)

 


CAPSTONE THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)

 

Delaware   000-21214   86-0585310
(State or other jurisdiction of incorporation)   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

1275 West Washington Street, Suite 101, Tempe, Arizona   85281
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:
(602) 286-5520

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

 

Section 4 – Matters Related to Accountants and Financial Statements

 

Item 4.01Changes in Registrant’s Certifying Accountant

 

 

(b) Engagement of New Independent Registered Public Accounting Firm.

 

On August 10, 2017, the Company engaged Eide Bailly LLP (“EB”) as its new independent registered public accounting firm. The decision to engage EB was approved by the Audit Committee of the Company’s Board of Directors.

 

During the Company’s two most recent fiscal years and in the subsequent interim period from January 1, 2017 through August 10, 2017, neither the Company nor anyone acting on its behalf consulted with EB regarding any of the matters or events set forth in Item 304(a)(2) of Regulation S-K.

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: August 14, 2017 CAPSTONE THERAPEUTICS CORP.
     
/s/ John M. Holliman, III
  John M. Holliman, III
  Executive Chairman